We conducted a multi-center retrospective cohort analysis of HR+/HER2+ stage IV breast cancer patients, explicitly evaluating treatment utilization and overall survival among patients treated with hormonal therapy or chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.